COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
adesso SE reports dynamic sales growth of 13% and a disproportionately high increase in EBITDA of 21% for the first half of the year / Full-year forecast confirmed
adesso SE reports 13% sales growth and 21% EBITDA increase in H1 2026. Full-year forecast confirmed. GenAI drives growth in cloud transformation and AI -
COMMUNIQUÉ DE PRESSE
SFC Energy achieves record first half with a strong increase in profitability – Forecast 2026 narrowed on the upside
SFC Energy AG achieves record first half with a strong increase in profitability. Forecast for 2026 narrowed on the upside, highlighting growth and strategic positioning -
-
COMMUNIQUÉ DE PRESSE
NORMA Group launches second public share buyback offer with a total volume of approximately EUR 208 million
NORMA Group launches second public share buyback offer totaling approximately EUR 208 million. Offer price at EUR 22.35 per share includes a 25.47% premium. Company aims to complete capital return to shareholders -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: NORMA Group SE: Management Board initiates public share buyback offer with a volume of approximately EUR 208 million for up to a total of 9,306,487 shares
NORMA Group SE Management Board initiates public share buyback offer of approximately EUR 208 million for up to 9,306,487 shares, following the resolution at the Annual General Meeting -
-
COMMUNIQUÉ DE PRESSE
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
European Medicines Agency validates Pfizer and Valneva's MAA for Lyme Disease Vaccine Candidate based on Phase 3 results. Potential game-changer in Lyme disease prevention -
COMMUNIQUÉ DE PRESSE
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
Pfizer et Valneva soumettent leur candidat vaccin hexavalent contre la maladie de Lyme à l'examen de l'EMA. Le vaccin PF-07307405 présente une efficacité de plus de 70 % selon l'étude VALOR -
COMMUNIQUÉ DE PRESSE
Nagarro presents Q2 and H1 2026 numbers, posts 2.0% and 4.2% YoY revenue growth in constant currency in Q2 and H1 2026, respectively
Nagarro SE presents Q2 and H1 2026 financial results with 2.0% and 4.2% YoY revenue growth in constant currency. EBITDA and net profit details shared
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
